CN103285030A - Xanthan gum-containing anti-blocking preparation - Google Patents
Xanthan gum-containing anti-blocking preparation Download PDFInfo
- Publication number
- CN103285030A CN103285030A CN2012100471015A CN201210047101A CN103285030A CN 103285030 A CN103285030 A CN 103285030A CN 2012100471015 A CN2012100471015 A CN 2012100471015A CN 201210047101 A CN201210047101 A CN 201210047101A CN 103285030 A CN103285030 A CN 103285030A
- Authority
- CN
- China
- Prior art keywords
- xanthan gum
- preparation
- adhesion
- content
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the technical field of medicines, and discloses a xanthan gum-containing preparation which is used for preventing and treating tissue adhesion after a surgery. The main component of the preparation is xanthan gum; and other parting agents and pharmacologically active substances, such as anticoagulants, anti-inflammatory agents, calcium channel blockers, cell growth inhibitors and proteolytic enzymes can be added into the main component to prepare a composite preparation for use; and the form can be gels, powder aerosols or film agents. The preparation disclosed by the invention has a significant effect on preventing the adhesion after the surgery, and has the advantages of good effect, stable quality, convenience in use and the like compared with other anti-blocking medicaments and blocking agents.
Description
Technical field
The invention belongs to medical technical field, is the preparation for tissue adhesion behind prevention and the treatment surgical operation that a class contains xanthan gum.
Background technology
Adhesion often betides after abdominal cavity, gynecological, orthopaedics, cardiothoracic surgery and the orthopaedic surgery, can cause serious clinical complication, as intestinal obstruction, abdominal cavity and pelvic pain, infertility etc., increased the difficulty of operation again, and further complication may take place.The purpose of Film with Preventing Adhesion is to eliminate or reduce the order of severity or the scope of adhesion generation, and then prevents that the complication that is caused by adhesion from occurring.The anti measure of adopting at present mainly is by the raising operation skill and uses adjuvant that though can play the effect of prevention of postoperative adhesion, effect is not certainly.Hyaluronic acid is widely used in the operations such as abdominal cavity, gynecological, tendon and cardiovascular for the anti-effective medicine of tissue adhesion.At present, clinical use hyaluronic acid remains in deficiency, and big inadequately as molecular weight, concentration is lower, and the interior holdup time of body is short etc.
Xanthan gum is the outer acidic polysaccharose of being produced by bacterial fermentation of a kind of born of the same parents, because the high viscosity of its good physico-chemical property-dispersion liquid, thixotropy, stability etc. are paid close attention to and studied.Xanthan gum anti mechanism and hyaluronic acid are similar: 1. the dissolving back forms the polymolecular network structure, and wounded tissue is separated with normal serous coat, plays space obstacle effect and lubrication, reduces friction; 2. suppress hemorrhage and ooze out, reduce the clot quantity that can form permanent adhesion skeleton; 3. suppress post-operation inflammatory cell migration and phagocytosis, suppress platelet deposition, promote wound healing; 4. stimulate growth and the differentiation of serous coat cell, make the wound serous coat reach the physiological reparation.But because hyaluronic acid decomposes easily in vivo and absorbed in the body, limited preventing tissue adhesion effect.Compare with it, xanthan gum also has excellent biological compatibility, but its stability is better than hyaluronic acid, be difficult for by the enzyme in the body and free radical cracking, in vivo the holdup time long, can obtain better longer effect for post-operation adhesion preventing.Use xanthan gum to prevent the postoperative tissue adhesion, can reduce the incidence rate of adhesion greatly.If be made into compound preparation with the xanthan gum gel as carrier and other interleaving agent and pharmacological active substance, with simple xanthan gum gel phase ratio, can obtain better preventing adhesiving effect.
Xanthan gum anti powder spray is preventing being better than xanthan gum solution and gel aspect the tissue adhesion.Xanthan gum solution and gel are comparatively fast disperseed in vivo because concentration is low, have weakened it at the iris action of tissue surface.After the xanthan gum powder spray is sprayed on tissue surface, a process of progressively dissolving is arranged, form the high concentration gel simultaneously in the part, retention time is long in local viscoelasticity height and the body, forms barrier effectively in the serous coat reparation phase, so its preventing adhesiving effect is obvious.Xanthan gum anti membrane can spread on intraperitoneal after laparotomy ventrotomy, the size of applying epiphragma can be according to age, body weight, sex, symptom, and intraperitoneal damaged area and being selected.
The xanthan gum anti quality of the pharmaceutical preparations is stable, and using method is simple, meets the requirement of clinical use.The chemical property of xanthan gum is stable, does not produce physical and chemical reaction with the most drug compatibility, can use with compatibilities such as many anticoagulant, hormone, anti-inflammatory analgesics.
Summary of the invention
An object of the present invention is to provide a class and contain the anti preparation that xanthan gum is active component.
Another object of the present invention also be to provide a kind of can same anticoagulant, antiinflammatory, proteolytic enzyme, calcium channel blocker, cytostatic agent and other interleaving agent be made into compound preparation, constituting a series of is the anti preparation of carrier with the xanthan gum.Anticoagulant such as dicoumarol, heparin, hirudin etc., antihistaminics such as antiinflammatory such as promethazine, hormones such as dexamethasone, hydrocortisone, andrographolide, NSAID (non-steroidal anti-inflammatory drug) such as ibuprofen, oxyphenbutazone, tolmetin; Calcium channel blocker example hydrochloric acid diltiazem, nifedipine, verapamil hydrochloride; Cytostatic agent such as fluorouracil; Protein hydrolytic reagent such as hyaluronidase, streptokinase, urokinase, pepsin, trypsin, cytoplastin, plasminogen; Other interleaving agent such as dextran, polyvinylpyrrolidone (PVP), carboxymethyl cellulose (CMC), agar, albumin, Oleum Camphora, chondroitin sulfate, fat, Radix Acaciae senegalis, carrageenan, olive oil, paraffin, phospholipid, polysiloxanes, vaseline, gelatin, oxidized regenerated cellulose, expanded polytetrafluoroethylsealing etc.
The contained xanthan gum of preparation of the present invention is prepared by bacterial fermentation, through centrifugal, filter, enzymolysis (acid, neutral, basic protein enzymolysis, bacteriolyze enzymolysis etc.), precipitate with ethanol prepared such as (ethanol, isopropyl alcohols etc.) and the high-purity xanthan gum.The xanthan gum average molecular mass is 2,000,000～2,000 ten thousand, and is preferred 5,000,000～8,000,000, and impurity content is less than 0.1%.
The present invention contains xanthan gum anti preparation, and its form can be gel, powder spray or membrane, all can prepare according to a conventional method.
Prescription and amount ranges that the present invention contains the xanthan gum preparation are: xanthan gum content is 1%～10% in gel or the membrane, xanthan gum content is 1%～100% in the powder spray, and when adding other interleaving agent, its content is 0～99%, when adding other medicines, its content meets the pharmacopeia regulation.
Owing to contain xanthan gum in the preparation of the present invention, but useful effect is in the adhesion position, because of its good biocompatibility, do not influence normal wound healing, xanthan gum retention time in vivo is long, and the barrier action during repair in trauma is obvious, so its preventing adhesiving effect is remarkable, through zoopery and clinic trial, prevention and the posterior synechiae for the treatment of surgical operation, it is all better than the effect of other medicines and barrier to reduce post-operative complication.
The specific embodiment
Following examples are for the present invention is described better, are not restriction the present invention.
Embodiment one: gel among the present invention, in 100 milliliters, get xanthan gum 3 grams, it is standby to add an amount of normal saline swelling, gets the Dextran 10 gram, dexamethasone sodium phosphate 0.1 gram, after adding the suitable quantity of water dissolving, mix with above-mentioned xanthan gum swelling solution, moisturizing is to volume, the high-speed stirred mixing gets compound gel of the present invention.
Embodiment two: powder spray among the present invention, in 100 grams, get xanthan gum 60 grams, and the Dextran 40 gram, coating-dividing sealing behind the mixing is sterilized with oxirane or microwave, gets powder spray of the present invention.
Embodiment three: powder spray among the present invention, in 100 grams, get xanthan gum 10 grams, and dexamethasone sodium phosphate 0.1 gram, all the other are dextrans, and each is with behind oxirane or the microwave sterilizating, and mixing packing in proportion gets powder spray of the present invention.
Embodiment four: membrane among the present invention, in 100 milliliters, getting xanthan gum 3 gram, to add an amount of dissolving of water standby, gets polyvinyl alcohol 3 grams, the Dextran 10 gram, after adding an amount of dissolving of water, with the abundant stirring and evenly mixing of above-mentioned xanthan gum solution, pour in the film forming device dry back film forming into, encapsulation gets membrane of the present invention.
Embodiment five: the anti efficiency evaluation
Select the healthy rabbits (1.5～2.0 kilograms of body weight) of Pass Test animal standard for use, use urethane anesthesia and carry out the center line laparotomy ventrotomy.Dissect the body wall peritoneum (about 1 cm thick) of 10 centimetres of one 3 cm x from a flank membranous wall.Close on the serosa surface of large intestine and swipe with a dissecting knife, until bleeding occurring.Part between the large intestine serous coat of the body wall peritoneum that excises and vicinity is used for estimating preventing adhesiving effect.Body wall peritoneum of the same area is excised at the place in the corresponding peritoneal wall of opposite side, and contiguous large intestine serous coat is also done above-mentioned similar scraping.Both sides are scraped erasure one side and are used normal saline, opposite side Application Example two, and powder spray is used for the effectiveness of anti-tissue adhesion among evaluation the present invention.Application and comparing result see Table 1.
The test of table 1 rabbit adhesion test contains the preventing adhesiving effect of xanthan gum powder spray
Embodiment two compares with the normal saline group:
*: P＜0.05
Can find out that from table 1 two groups of embodiment compare with the normal saline group, mucosa adhesion degree obviously reduces.Illustrate that the present invention has significant preventing adhesiving effect, has excellent biological compatibility and biological safety simultaneously.
Embodiment six: the xanthan gum gel with contain the contrast of xanthan gum gel compound preparation (embodiment one) and powder spray (embodiment two) preventing adhesiving effect.
Animal anti model is set up with embodiment five.Both sides are scraped erasure one side and are used 3% xanthan gum anti-adhesion gel, opposite side Application Example one or embodiment two.Application and comparing result see Table 2.
The preventing adhesiving effect of table 2 preparation of the present invention and 3% xanthan gum gel relatively
The embodiment of the invention one, two is compared with xanthan gum gel group:
*: P＜0.05
Can find out that from table 2 embodiment one, two groups compare with 3% xanthan gum gel group, mucosa adhesion degree obviously reduces.Illustrate that the present invention contains the simple xanthan gum gel of xanthan gum preparation and has better preventing adhesiving effect, have clinical use value.
The evaluation criterion of adhesion degree is as follows:
0: no adhesion;
I: film like adhesion (separable);
II: slight adhesion (inseparable-covered about 35% test area);
III: moderate adhesion (inseparable-covered about 35%～60% test area);
IV: serious adhesion (inseparable-covered the test area greater than 60%).
Claims (6)
1. a class contains the anti preparation of xanthan gum, it is characterized in that containing the active component xanthan gum in the described preparation, also contains other adjuvant and pharmacological active substance and is made into compound preparation, tissue adhesion after being used for prevention and treating surgical operation.
2. the described xanthan gum anti preparation that contains of claim 1 is characterized in that xanthan gum is the high-purity xanthan gum that separation and purification obtains behind microbial fermentation.
3. according to the described high-purity xanthan gum that separation and purification obtains behind microbial fermentation of claim 2, it is characterized in that the xanthan gum average molecular mass is 2,000,000～2,000 ten thousand, preferred 5,000,000～8,000,000, impurity content is less than 0.1%.
4. the described xanthan gum anti preparation that contains of claim 1, its form can be gel, powder spray or membrane.
5. the described xanthan gum anti preparation that contains of claim 1 is characterized in that adding other interleaving agent and pharmacological active substance and conventional pharmaceutic adjuvant as required in the prescription is made into compound preparation.
6. the described xanthan gum anti preparation that contains of claim 1 is characterized in that xanthan gum content is 1%～10% in gel or the membrane, and xanthan gum content is 1%～100% in the powder spray, when adding other interleaving agent, its content is 0～99%, and when adding other medicines, its content meets the pharmacopeia regulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100471015A CN103285030A (en) | 2012-02-28 | 2012-02-28 | Xanthan gum-containing anti-blocking preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100471015A CN103285030A (en) | 2012-02-28 | 2012-02-28 | Xanthan gum-containing anti-blocking preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103285030A true CN103285030A (en) | 2013-09-11 |
Family
ID=49086919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100471015A Pending CN103285030A (en) | 2012-02-28 | 2012-02-28 | Xanthan gum-containing anti-blocking preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285030A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948623A (en) * | 2014-05-04 | 2014-07-30 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhalation for orthopedic surgery and preparation method thereof |
| CN104825386A (en) * | 2015-05-25 | 2015-08-12 | 湖北汇瑞药业股份有限公司 | Epidermal anesthesia gel and preparation method thereof |
| CN112043879A (en) * | 2020-09-15 | 2020-12-08 | 山东奥能医疗科技有限公司 | Carboxymethyl chitosan surgical anti-adhesion gel and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994277A (en) * | 1989-10-31 | 1991-02-19 | Pfizer Hospital Products Group, Inc. | Use of xanthan gum for preventing adhesions |
-
2012
- 2012-02-28 CN CN2012100471015A patent/CN103285030A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994277A (en) * | 1989-10-31 | 1991-02-19 | Pfizer Hospital Products Group, Inc. | Use of xanthan gum for preventing adhesions |
Non-Patent Citations (1)
| Title |
|---|
| 赵景联: "黄原胶的特性、生产及应用", 《现代化工》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948623A (en) * | 2014-05-04 | 2014-07-30 | 青岛市城阳区人民医院 | Anti-adhesion dry powder inhalation for orthopedic surgery and preparation method thereof |
| CN103948623B (en) * | 2014-05-04 | 2016-08-31 | 青岛市城阳区人民医院 | A kind of bone surgery anti powder spray and preparation method thereof |
| CN104825386A (en) * | 2015-05-25 | 2015-08-12 | 湖北汇瑞药业股份有限公司 | Epidermal anesthesia gel and preparation method thereof |
| CN112043879A (en) * | 2020-09-15 | 2020-12-08 | 山东奥能医疗科技有限公司 | Carboxymethyl chitosan surgical anti-adhesion gel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2578678C (en) | Photoreactive polysaccharide, photocrosslinked polysaccharide products, the method of making them and medical materials therefrom | |
| JP5489999B2 (en) | Surgical hydrogel | |
| CN101583348B (en) | Formation of medically useful gels comprising microporous particles and methods of use | |
| CN102231985B (en) | Composition for preventing adhesion | |
| Li et al. | Preparation and the hemostatic property study of porous gelatin microspheres both in vitro and in vivo | |
| WO2009018764A1 (en) | An absorbable modified starch hemostatic material and perparation thereof | |
| KR20170093243A (en) | Flowable hemostatic composition | |
| CN102399295A (en) | Low-sulfhydrylation-modification-degree biocompatible high-molecular sulfhydrylation derivatives, cross-linking material thereof, and purpose thereof | |
| JP2021020907A (en) | Pharmaceutical composition comprising modified fucan for use in treatment of fibrous adhesions and other disorders | |
| JP2001526246A (en) | Methods and compositions for drug delivery and / or adhesion prevention | |
| KR102350526B1 (en) | Method of preparing wound dressing composition for treating skin wounds having improved aggregation | |
| Song et al. | Facile preparation of drug-releasing supramolecular hydrogel for preventing postoperative peritoneal adhesion | |
| Cai et al. | Physically cross-linked hyaluronan-based ultrasoft cryogel prepared by freeze–thaw technique as a barrier for prevention of postoperative adhesions | |
| CN103285030A (en) | Xanthan gum-containing anti-blocking preparation | |
| CN1116044C (en) | Antisticking particle and powder containing sodium hyaluronate and their preparation process | |
| JP6916353B1 (en) | Polymer composition for preventing adhesions | |
| KR101668349B1 (en) | Adhesion barrier agent | |
| KR101845885B1 (en) | Manufacturing method of thermosensitive anti-adhesion compositions based on micronized acellular dermal matrix | |
| Hyon et al. | Evaluation of the optimal dose for maximizing the anti-adhesion performance of a self-degradable dextran-based material | |
| Sharma et al. | A review: formulation and evaluation of pharmaceutical gel | |
| CN105126153A (en) | Composite hemostatic film with thrombin and preparing method of composite hemostatic film | |
| CN102755663A (en) | Formula of medical biocolloid solution and preparation method thereof | |
| WO2017060821A1 (en) | Hemostatic composition | |
| KR20140037463A (en) | Anti-adhesive composition for forming liquid foam | |
| KR20120091717A (en) | Anti-adhesion agent comprising curdlan and gellan gum, and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130911 |